Magnetar Financial LLC Makes New Investment in ADMA Biologics Inc $ADMA

Magnetar Financial LLC acquired a new stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 108,085 shares of the biotechnology company’s stock, valued at approximately $1,585,000.

Other institutional investors have also modified their holdings of the company. American Century Companies Inc. lifted its position in ADMA Biologics by 8.4% in the second quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company’s stock worth $83,966,000 after buying an additional 358,627 shares during the last quarter. Thrivent Financial for Lutherans increased its position in ADMA Biologics by 24.9% during the third quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock valued at $60,719,000 after acquiring an additional 826,415 shares during the last quarter. Ranger Investment Management L.P. increased its position in ADMA Biologics by 49.1% during the second quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock valued at $43,529,000 after acquiring an additional 786,865 shares during the last quarter. WINTON GROUP Ltd raised its stake in shares of ADMA Biologics by 302.8% in the second quarter. WINTON GROUP Ltd now owns 272,817 shares of the biotechnology company’s stock valued at $4,968,000 after acquiring an additional 205,094 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of ADMA Biologics in the third quarter valued at $877,000. 75.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ADMA. Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Finally, Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat, ADMA Biologics presently has an average rating of “Buy” and a consensus target price of $32.00.

ADMA Biologics Stock Down 4.3%

Shares of NASDAQ:ADMA opened at $14.99 on Friday. The business’s 50 day moving average is $16.69 and its 200 day moving average is $16.72. The stock has a market cap of $3.57 billion, a P/E ratio of 24.98 and a beta of 0.51. ADMA Biologics Inc has a 52-week low of $13.76 and a 52-week high of $25.67. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million during the quarter, compared to analyst estimates of $139.80 million. During the same period in the previous year, the company posted $0.46 EPS. ADMA Biologics’s revenue was up 18.4% on a year-over-year basis. Sell-side analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Insider Activity

In other ADMA Biologics news, Director Steve Elms acquired 7,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was bought at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the purchase, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. The trade was a 0.34% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the transaction, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 3.50% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.